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Abstract
Etiology of aberrant social behavior consistently points to a strong polygenetic component involved in fundamental
developmental pathways, with the potential of being enhanced by defects in bioenergetics. To this end, the occurrence of
social deficits and mitochondrial outcomes were evaluated in conditional Pten (Phosphatase and tensin homolog) haplo-
insufficient mice, in which only one allele was selectively knocked-out in neural tissues. Pten mutations have been linked to
Alzheimer’s disease and syndromic autism spectrum disorders, among others. By 4–6 weeks of age, Pten insufficiency
resulted in the increase of several mitochondrial Complex activities (II–III, IV and V) not accompanied by increases in
mitochondrial mass, consistent with an activation of the PI3K/Akt pathway, of which Pten is a negative modulator. At 8–13
weeks of age, Pten haplo-insufficient mice did not show significant behavioral abnormalities or changes in mitochondrial
outcomes, but by 20–29 weeks, they displayed aberrant social behavior (social avoidance, failure to recognize familiar
mouse, and repetitive self-grooming), macrocephaly, increased oxidative stress, decreased cytochrome c oxidase (CCO)
activity (50%) and increased mtDNA deletions in cerebellum and hippocampus. Mitochondrial dysfunction was the result of
a downregulation of p53-signaling pathway evaluated by lower protein expression of p21 (65% of controls) and the CCO
chaperone SCO2 (47% of controls), two p53-downstream targets. This mechanism was confirmed in Pten-deficient striatal
neurons and, HCT 116 cells with different p53 gene dosage. These results suggest a unique pathogenic mechanism of the
Pten-p53 axis in mice with aberrant social behavior: loss of Pten (via p53) impairs mitochondrial function elicited by an early
defective assembly of CCO and later enhanced by the accumulation of mtDNA deletions. Consistent with our results, (i)
SCO2 deficiency and/or CCO activity defects have been reported in patients with learning disabilities including autism and
(ii) mutated proteins in ASD have been found associated with p53-signaling pathways.
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Introduction
Phosphatase and tensin homolog on chromosome ten (Pten) is a
tumor suppressor gene mutated in many human cancers [1].
While loss of both alleles seems relevant for tumorigenesis, clinical
expressions of inherited Pten mutations had been linked to benign
hamartomas, macrocephaly, seizures, ataxia, mental retardation,
autism and, more recently, to Alzheimer’s disease [1–10]. Pten
mutations have been reported in cases of autism, particularly in a
subset of patients with macrocephaly, suggesting that mutations in
this gene might be one of the genetic risk factors for human ASDs
[9–13]. Kwon et al [14] showed that conditional Pten null mice
resulted in impaired social interaction and learning, no preference
for social novelty, limited nest-forming activity, as well as
abnormal anxiety levels [14]. These mice showed activation of
the Akt/mTOR/S6k pathway and inactivation of GSK3b [15]
suggesting that abnormal activation of the PI3K/Akt pathway in
specific neuronal populations could underlie the observed macro-
cephaly and behavioral abnormalities. In another study, the
GFAP-Cre transgenic line used to drive Cre activity in Pten cKO
mice induced conditional deletion of Pten in astrocytes as well as in
some neuronal populations (hippocampal, cerebellar granule and
pyramidal neurons [16]). Neurons from these .10-weeks old mice
exhibited increased mitochondrial size (megamitochondria) along
with defects in synaptic structures and myelination [17]; however,
no data on mitochondrial function or activities is currently
available for this model. Of interest, it has been reported that
overexpression of Pten had a profound effect in intermediary
metabolism of mice, increasing their energy expenditure and
decreasing fat deposits [18], suggesting a link between Pten and
energy metabolism.
The present study was designed to expand earlier work
performed with the conditional Pten (phosphatase and tensin
homolog) null mouse by studying mitochondrial function in 3
brain regions, namely cortex, hippocampus and cerebellum. To
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this end, social and repetitive behavior was tested in heterozygous
Pten+/loxP (HET) and heterozygous Nse-cre+/2; Pten+/loxP (HET-
CRE) mice aged 4–29 weeks (Table 1), along with the evaluation
of mitochondrial enzymatic activities, mtDNA copy number and
mtDNA deletions, in cerebellum, hippocampus and cortex.
Considering that a subset of individuals with ASD who presented
macrocephaly had only one mutated Pten allele [9,19,20], not a
complete knock-out as used in Kwon et al. [14], we used
conditional Pten knock-out mice in which only one allele of Pten
was selectively knocked-out in neurons to better resemble the
genotype and phenotype of these patients without increasing
significantly the risk or incidence of cancer which may obscure the
outcomes.
Our study is the first one at providing a thorough and
comprehensive analysis of mitochondrial activities during Pten
haplo-insufficiency and a mechanism based on a negative feedback
loop between two tumor suppressors, Pten and p53, that results in
altered bioenergetics in mice with social deficits.
Results
Pten haplo-insufficiency in cerebellum and hippocampus
of mice
Conditional Pten knock-out mice were obtained by flanking
exon 5, which encodes the phosphatase domain of Pten, between
LoxP sequences [21]. To generate a Cre-mediated exon 5 deletion
of Pten, we crossed PtenloxP/loxP animals with the Nse-Cre+/2
transgenic mice aimed for neural tissue-specific deletion. The mice
utilized in this study were considered controls (i.e., named HET
for heterozygous Pten+/loxP) or Pten-haploinsufficent (i.e. named
HET-CRE for heterozygous Nse-cre+/2; Pten+/loxP), aged 4 to 29
weeks.
Immunohistochemistry performed in brain slices with antibod-
ies to Cre-recombinase showed that the deletion of Pten was mainly
restricted to cerebellum and hippocampus (not shown) as reported
by others [14,22]. Cre immunostaining was minimal at early
postnatal days, increasing from 8–13 weeks (not shown) coinci-
dentally with the occurrence of Pten gene deletion in these brain
regions (Figure 1A, Figure S1). The efficiency of the Cre-
mediated deletion of Pten in HET-CRE mice aged 8–13 weeks was
4364% for neural tissues when compared to HET mice (near
haploid; Figure 1A). Pten protein expression was not statistically
different between HET and HET-CRE mice aged 4–6 weeks in
cortex (Figure 1B), whereas in cerebellum and hippocampus the
decrease was significant in HET-CRE (69% of HET, p,0.05 and
44% of HET, p,0.00005 respectively; Figure 1C, D). At 8–13
weeks, Pten protein expression in HET-CRE cerebellum and
hippocampus was (average of these two regions) 5061% of HET
values, decrease still sustained at 20–29 weeks (5961% vs. 8–13
weeks, p=0.356). No significant decrease in Pten levels were
observed at any age (4–29 weeks old) in cortex from HET-CRE
mice. This result could be explained by the different spatial and
temporal expression of Cre in various brain regions [23–25];
alternatively, the apparent lack of Pten knockdown in cortex could
result from a compensatory response from glia, masking the
decrease in neurons. Consistent with this hypothesis, the levels of
glial fibrillary acidic protein (determined by western blots
normalized to actin) were higher in HET-CRE cortex than in
HET mice aged 20–29 weeks (0.5060.09 vs. 0.1360.05;
p=0.025). As expected, in non-neural tissues (liver and heart),
Pten protein expression in HET-CRE (expressed as a percentage
of HET values) was not significantly different from HET
(Figure 1E).
Development of macrocephaly in Pten-haploinsufficient
mice
Brain hypertrophy and overgrowth of cortex and hippocampus
were observed in haplo-insufficient Pten mice consistent with the
macrocephaly reported in Pten null mouse model [14] and that
observed in children with autism who harbor Pten mutations
[9,10,26]. Macrocephaly and the occurrence of aberrant social
behavior was observed in a few mice at 8–13 weeks of age (only 2
of 7 mice presented macrocephaly and 1 of 7 presented abnormal
behavior; n=7/group; p=0.433) becoming significantly different
at .20 weeks of age. At 20–29 weeks, brain weight (normalized to
body weight) was significantly higher in HET-CRE than HET
(10%; p,0.05; Figure 1F). The enlargement of cortex and
hippocampus in HET-CRE was respectively 1.7- and 2.5-fold of
controls (p,0.05; Figure 1F), whereas the change in cerebellum
was more modest (5%; p,0.05; Figure 1F). The apparent
discrepancy between cortex and hippocampus overgrowth com-
pared to that in cerebellum could be explained by considering
brain-region specific outcomes (i.e., tissue-specific distribution of
Cre [15] and/or contribution of gliosis). In this regard, gliosis
might play a more relevant role in cortex, whereas macrocephaly
with neuronal hypertrophy [14–16], enlarged caliber of neuronal
projections and increased dendritic spine density [14,17] –as
observed in Pten conditional KO mice- would in cerebellum and
hippocampus given the relatively higher glia-to neuron ratio in
cortex than in the other two brain regions (3.7, 0.4 and 0.2 in
cortex, hippocampus and cerebellum, respectively [27,28]). In
addition, a reciprocal correlation between cortex frontal lobe and
cerebellum sizes has been observed in children with autism [29]
indicating interactions between brain regions. The observations
performed with our model (one-allele) were consistent with those
from conditional Pten null mice in which the development of
Table 1. Characteristics of the mouse groups and tests performed.
Age range (weeks) Tests performed HET-CRE HET p-value
n F M
Age
(wk) n F M
Age
(wk)
4–6 BMB, H, 7 4 3 4.660.1 8 4 4 4.960.2 0.178
8–13 BMB, H, B, BW 7 4 3 10.760.5 11 5 6 10.860.4 0.947
20–29 BMB, B, BW 6 3 3 2463 10 5 5 24.560.8 0.759
The age range represents the 95% Confidence interval age limits in weeks and the age of the group in weeks was expressed as mean 6 SEM. Abbreviations: BMB,
molecular tests in biochemistry and molecular biology; H, histology; BW, brain weight; B, behavior; F, female, M, male. The p-values were obtained by comparing the age
of HET-CRE to that of HET.
doi:10.1371/journal.pone.0042504.t001
Pten-p53, Mitochondria and Social Deficits
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Figure 1. Changes of Cre-mediated expression of Pten protein and gene with age in brain from Pten haplo-insufficient mice. HET and
HET-CRE groups were sex- and age matched and at each age and each group had 7 to 11 animals (See Table 1). All values were expressed as mean
6 SEM. Panels A–D: HET, white bars; HET-CRE, black bars. Panel A: Pten gene deletion in various brain regions from HET-CRE mice aged 8–13 weeks.
Pten gene deletion was calculated as the ratio of the truncated band over that of the normal allele for Pten exon 5 determined as described in the
Pten-p53, Mitochondria and Social Deficits
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macrocephaly and aberrant social behavior seemed to reflect a
gene-dose effect (one- vs. two-allele deletion) rather than an age-
dependent onset for the development of abnormal behavior. In
this regard, appearance of macrocephaly (7% increase in brain
weight) and aberrant social behavior in the conditional Pten null
model was observed by 1–1.5 months becoming statistically
significant at 2 to 3 months of age (17% increase; [14,15]).
Social behavior and self-grooming activity in HET-CRE
mice
Sociability (the tendency to spend time with another conspecif-
ic), preference for social novelty, and the ability to discriminate
and choose between familiar and new conspecifics were tested in
Het and HET-CRE mice [30,31].
During the socialization trial, the test mouse is placed in the
center compartment of a three-chambered test box, and given a
choice between spending time in the side containing an unfamiliar
(stranger) conspecific mouse, or spending time in the third of the
box occupied by a control object (an empty cup), to measure
exploration of something that has no social valence (non-social
side). The stranger mouse is contained within a small wire cage
(identical to the one occupied by the cup in the non-social side of
the box), to allow exposure to visual, auditory, olfactory, and some
tactile stimuli, while preventing aggressive or sexual interactions.
Measures taken during the trial include number of entries and
time spent in each side of the box, and time spent sniffing each
wire cage.
Analysis of the scores obtained during the socialization
interaction trial showed that, while the number of entries
(frequency) in the social side of the chamber were the same in
the two groups of mice, HET mice spent more time (1.3-fold;
p=0.014) with the social target than HET-CRE mice (social side
time; Table 2). Two other outcomes were also recorded during
the socialization trial: sniff time and sniff frequency. Sniff
frequency was defined as the number of times the mouse sniffed
the inanimate target and/or the social target. Sniff time was
considered as the cumulative time that the test mouse spent
sniffing the inanimate target (nonsocial) and/or the social target
(social). While no differences were recorded for the sniff
frequencies between the two groups, HET mice spent 1.3-fold
(p=0.05) more time than HET-CRE mice sniffing the social target
(Table 2). The social avoidance score in HET mice, defined as
the difference between social side and non-social side times, was
3.7-fold of HET-CRE mice (p=0.006). This score underlines the
finding that HET-CRE mice exhibit less preference for socializa-
tion than HET mice.
The novelty preference trial presented the test mouse with a
familiar mouse versus a novel one (in place of the cup used during
the socialization trial; Table 2). Once again, while no difference
was observed between the two groups in the number of entries to
the novel target, HET-CRE mice had lower novel to total side
time ratio (83% of HET; p=0.04; Table 2), confirming that
HET-CRE mice did not show a preference for social novelty, in
agreement with the findings on Nse-cre PtenloxP/loxP [14]. During
the novelty preference trial, the sniff frequency, defined as the
number of times the test mouse sniffed the novel mouse
normalized by the total number of times the mouse sniffed both
familiar and novel targets, was not significantly different between
the two groups. However, the time spent by the test mouse sniffing
the novel mouse normalized by the total sniff time was significantly
lower in HET-CRE mice (60% of HET; p=0.05) than HET mice
(Table 2).
The results of the socialization and novelty trials suggested that
HET-CRE mice showed a social avoidance preference (more time
spent with inanimate object than with mouse and less time at
interacting with a novel mouse, respectively) with a failure to
recognize the familiar mouse (more time spent with familiar than
novel mouse).
A separate behavioral test was used to evaluate repetitive
behavior as judged by the time spent by the test mouse in self-
grooming activities. In terms of repetitive behavior, HET-CRE
mice showed twice the frequency of self-grooming than HET mice
(defined as the cumulative time in seconds spent self-grooming
scored over a 15-min session; Table 2; p=0.03). These results
suggested the occurrence of repetitive behavior (or insistence of
sameness) in 20–29 weeks old HET-CRE mice.
Although only one HET-CRE mouse (out of 7) started to show
aberrant social behavior by 8–13 weeks, none of the behavioral
tests were significantly different in this age group.
Methods S1. Panels B–D: Pten protein expression in brain regions from HET and HET-CRE mice aged 4–6, 8–13, and 20–29 weeks. The densitometry of
the Pten band obtained by Western blots was normalized to that of actin for each brain region. The p-values were obtained by using Student’s t-test.
Panel E: Pten gene deletion and Pten protein expression in liver and heart from HET and HET-CRE mice aged 8–13 weeks. Pten gene deletion was
obtained as described under 1A legend. Pten protein expression was calculated as described under Panel B–D legend but expressed as percentage
of age-matched HET values. Panel F: Assessment of macrocephaly in Pten haplo-insufficient mice. Mean values for HET mice at 20–29 weeks were
322615 mg brain wet weight; body weight 2463 g; 1.760.2 mg cerebellum/g body weight; 1.460.4 mg cortex/g body weight; 0.6660.06 mg
hippocampus/g body weight. * All values were significantly different from HET with P,0.05.
doi:10.1371/journal.pone.0042504.g001
Table 2. Behavioral tests performed on HET and HET-CRE
mice aged 20–29 weeks.
Outcome HET HET-CRE -fold p-value*
SOCIALIZATION TRIAL
{Social side time 0.5860.04 0.4560.04 0.78 0.014
{Social side frequency 0.4160.03 0.4660.03
Social/(Social+Nonsocial) sniff time 0.6060.04 0.4760.06 0.78 0.050
Social/(Social+Nonsocial) sniff
frequency
0.5660.03 0.5360.08
Social avoidance/Total side time 0.3360.06 0.0960.06 0.27 0.006
NOVELTY TRIAL
{Novel side time 0.5460.02 0.4560.04 0.83 0.041
{Novel side frequency 0.4160.01 0.3960.02
Novel/(Novel+Familiar) sniff time 0.6160.01 0.3660.09 0.59 0.050
Novel/(Novel+Familiar) sniff
frequency
0.5260.02 0.4860.05
SELF-GROOMING TEST 3263 6163 1.91 0.03
HET and HET-CRE values were expressed as mean 6 SEM. The fold increase
represents the ratio between HET-CRE and HET means.
*p-value calculated using the one-tailed t-test between two independent
means. For all comparisons, significance was set at p#0.050.
{Normalized by total trial time.
{Normalized by total trial frequency.
doi:10.1371/journal.pone.0042504.t002
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Mitochondrial outcomes in hippocampus cerebellum
and cortex from asymptomatic, 4–6 and 8–13 weeks Pten
haplo-insufficient mice
Several mitochondrial outcomes were tested in purified,
mitochondria isolated from cortex, cerebellum and hippocampus
from 4–6 and 8–13 weeks old Pten haplo-insufficient mice.
In HET-CRE mice 4–6 weeks old, higher Complex II–III
(SCCR=225% of HET values; p=0.045) and Complex IV
(CCO=277% of HET values; p=0.03) activities (hippocampus)
and increased Complex II–III (152% of HET; p=0.02) and
ATPase (146% of HET; p=0.04) activities (cerebellum) were not
accompanied by increased citrate synthase (CS, considered a
marker of mitochondrial mass [32]; average of two brain regions,
4–6 weeks = 96610% of HET) consistent with a lack of
mitochondrial biogenesis (Figure 2). No significant difference
was found in any of the activities tested in the 8–13 weeks old mice
in cerebellum or hippocampus. These results were consistent with
the findings obtained with the behavioral tests, which did not show
any significant difference between HET and HET-CRE at this age
group.
No differences in ETC activities were also observed in cortex, at
any age (Figure 2), consistent with the lack of Pten expression
change (Figure 1B).
A higher mtDNA copy number (1.45-fold of HET; p=661026)
was noted in cerebellum from 8–13 weeks old HET-CRE mice,
once again not accompanied by increases in CS activity,
suggesting a general response to oxidative stress in response to a
decreased energy production [33–35].
Mitochondrial outcomes in hippocampus, cerebellum
and cortex from symptomatic, 20–29 weeks Pten haplo-
insufficient mice
Compared to age-matched HET mice, significant decreases in
cytochrome c oxidase activity (CCO) were observed in HET-CRE
cerebellum (59%; p,0.05; Table 3, Figure 2) and hippocampus
(35%; p,0.05; Table 3, Figure 2) at 20–29 weeks. The content
of nitrated Tyr in ATPase b-subunit, a sensitive marker of nitrative
stress [36], in HET-CRE cerebellum was 1.9-fold of HET values
(p=0.01; Figure S2) suggesting an increased nitrative/oxidative
Figure 2. Changes in ETC activities in cerebellum, hippocam-
pus and cortex in HET and HET-CRE mice. Enzymatic activities
were evaluated as described in the Materials and Methods section and
originally expressed as nmol6(min6mg protein)21 and normalized to
citrate synthase activity for each brain region and age. Complex I
activity was evaluated by measuring either NFR (cerebellum and
hippocampus) or NQR (cortex) activities. Data were expressed as
percentage of HET values (mean 6 SEM) and analyzed by unpaired t
test. * p,0.05 compared with HET.
doi:10.1371/journal.pone.0042504.g002
Table 3. p53 and p53-downstream targets, CCO activity,
mtDNA copy number and deletions in Pten haplo-insufficient
mice aged 20–29 weeks.
Outcomea Cerebellum Hippocampus Cortex
mtDNA copy number 8668 8966 9169
mtDNA deletions(a) 1564* 3164** 961
Protein expression(b)
Pten 6567* 4766* 85620
p53 42612* 8363 10361
p21 5464** 6169* -
SCO2 4567* 57612** -
Activity
CCO/CS 4066* 45610** 11562
All outcomes were expressed as percentages of HET values. The values for the
outcomes from HET mice were the following: Hippocampus: mtDNA copy
number 12146178; mtDNA gene ratios for ND4, CYTB and COX3 = 0.8660.05,
1.2260.02 and 1.6560.3, respectively; CCO 235626 and CS
144614 nmol6(min6mg protein)21. Cortex: mtDNA copy number 15636177;
mtDNA gene ratios for ND4, CYTB and COX3 = 0.9260.06, 1.1260.01 and
1.560.2, respectively; CCO 245619 and CS 17069 nmol6(min6mg protein)21.
Cerebellum: mtDNA copy number 2600617; mitochondrial gene ratios for ND4,
CYTB and COX3= 0.8360.06, 1.0260.002 and 1.160.1, respectively; CCO 6066
and CS 15064 nmol6(min6mg protein)21.
(a)Percentage of mtDNA deletions were calculated as follows for each of the
three tissues: 1002(1006average of mitochondrial gene ratio HET-CRE/HET).
(b)Protein expression was performed by western blot and by normalizing the
intensity of the band of the loading control (actin) and expressed as percentage
of control values.
*p,0.05;
**p,0.01;
***p,0.001. Representative western blot images and densitometry results are
shown in Figures S3 and S4.
doi:10.1371/journal.pone.0042504.t003
Pten-p53, Mitochondria and Social Deficits
PLOS ONE | www.plosone.org 5 August 2012 | Volume 7 | Issue 8 | e42504
stress. Consistent with this hypothesis, significant mtDNA dele-
tions -at the segments encoding for ND4, COX3 and CYTB-
(Table 3) and higher MnSOD protein expression (2.5-fold of
HET; p,0.05 and 1.4-fold of HET; p=0.05) were observed in
cerebellum and hippocampus of HET-CRE mice compared to
HET (not shown). In contrast with cerebellum and hippocampus,
no significant differences were observed in cortex from HET and
HET-CRE mice.
Figure 3. Protein expression of p53, p21 and SCO2 and CCO activity in Pten-deficient striatal neurons. A. Representative Western blot
and densitometry of p-Akt and total Akt protein levels in striatal neurons. Results are expressed as the ratio between p-Akt and total Akt and reported
as mean 6 SEM. B. Representative Western blots of p53, p21 SCO2 and Tubulin. Forty mg of protein were loaded in each lane. Details on the
antibodies used are described in the Materials and Methods. C Densitometry results for p53, p21, SCO2 protein expression, normalized by Tubulin
(loading control). CCO activity was expressed as nmol6(min6106 cells)21 and reported normalized by citrate synthase. Results are mean 6 SEM of
experiments in triplicates.
doi:10.1371/journal.pone.0042504.g003
Pten-p53, Mitochondria and Social Deficits
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Pten haplo-insufficiency, p53 levels and cytochrome c
oxidase activity in 20–29 weeks old mice
Given the genetic interaction between Pten and p53 [37–43],
and considering that p53 is an upstream factor for the assembly of
CCO via Synthesis of Cytochrome c Oxidase 2 (SCO2) [44], we
hypothesized that the decrease in Pten expression in cerebellum
and hippocampus from HET-CRE mice could result in an altered
expression and/or transcriptional activity of p53 leading to lower
SCO2 protein expression and CCO activity.
Pten haplo-insufficiency resulted in decreased p53 protein
expression in cerebellum of HET-CRE mice (42% of HET,
p,0.05; Table 3, Figure S3), accompanied by a lower protein
expression of p21 and SCO2, two downstream effectors of p53
(p21= 54%; p,0.005; SCO2=45% of HET; p,0.05; Table 3,
Figure S3). Although p53 protein level was not found to be
significantly different in hippocampus of HET-CRE mice (83% of
HET, Table 3, Figure S4), p21 and SCO2 protein levels were
decreased (p21= 61% of HET; p,0.005; SCO2=57% of HET;
p,0.05; Table 3, Figure S4), suggesting an involvement of p53.
The apparent discrepancy between lack of p53 protein changes
and decreases in p21 and/or SCO2 can be bridged considering
that relatively small changes in p53 expression (or in its post-
translational modifications) are amplified through a signaling
cascade resulting in more evident changes in p53-downstream
targets [45–49].
No changes in p53, SCO2 or p21 protein levels were observed
at any age in cortex, or at 4–6 and 8–13 weeks in cerebellum
(Figure S3) or hippocampus (Figure S4).
Lower MW (,30 kDa) fragments resulting from caspase-
dependent cleavage of p53 during apoptosis [50] were not
evidenced by western blots performed with antibodies directed
towards either the N- (1C12 antibody, Cell Signaling) or C-
terminus (Invitrogen cat n. 134100) of p53 in all brain regions
from HET or HET-CRE mice (not shown) suggesting a limited
role for apoptosis in Pten haplo-insufficiency.
The differences between hippocampus and cerebellum could be
attributed to the tissue-dependent expression of Pten as well as that
of p53, p63, and p73, explaining why different brain regions (or
human cell types) respond differently to identical cellular damages
[51]. In addition, protein expression of mitochondrial Complexes
in brains from individuals with autism has been found affected
both in a tissue-specific and an age-specific manner [52] and
different functional abnormalities in frontal cortex, amygdala-
hippocampal (limbic) regions and cerebellum had been reported
[53–55]. These results indicated that Pten haplo-insufficiency in
HET-CRE cerebellum and hippocampus resulted in changes in
the expression of downstream targets of p53, and ultimately, in
changes in CCO activity.
Pten inhibition, p53 levels and cytochrome c oxidase
activity in striatal neurons
To confirm the results obtained with the Pten haplo-insufficient
mice, we used a different but still relevant biological model, striatal
neurons (STHdhQ7/Q7), in which Pten activity had been inhibited
by SF1670 [56]. Given that the phosphorylation of Akt at Ser-473
is regulated by PI3K through Pten [57], Western blots against
pAkt were performed to evaluate the SF1670-mediated inhibition
of Pten (Figure 3A). The phosphorylation of Akt (normalized to
total Akt) was 2.2-fold higher in SF1670-treated cells (p=0.004),
confirming the inhibition of Pten. P53, p21 and SCO2 protein
levels in SF1670-treated cells were decreased by 20%, 40% and
38%, respectively, of vehicle-treated neurons (p=0.02; p=0.01;
p=0.006; Figure 3B, C). In agreement with the results obtained
with the Pten haplo-insufficient mice, CCO activity was also
significantly lower in Pten-deficient neurons than controls (70% of
untreated, p=0.003; Figure 3C).
P53 acts as a negative regulator of Pten in HCT 116 cells
To test the hypothesis that direct changes in p53 could
modulate Pten activity, we tested the same outcomes as described
before but using p53+/+, p53+/2 and p532/2 human colon cancer
cells (HCT 116; Figure S5). P53 gene expression in p53+/2 and
p532/2 cells was 35% and ,10% compared to wild type (not
shown) and consistent with the p53 protein level of 40% (p,0.01)
and ,2% of p53+/+, respectively (Figures S5A & S5B). The
mtDNA copy number in p53+/2 cells was 1.3-fold of WT (Figure
S5C) with no apparent mtDNA deletions (consistent with the
results obtained with HET-CRE cerebellum aged 8–13 weeks), or
changes in MnSOD protein levels (Figures S5A & S5B).
MtDNA deletions were found significantly increased (2-fold,
p,0.05; Figure S5C) in p532/2 cells accompanied by a 1.8-
fold increase in MnSOD levels (p,0.05) relative to WT. To
elucidate the link between p53 and mtDNA copy number
maintenance [58], the gene expression of the mitochondrial
transcription factor A (TFAM) was evaluated in HCT 116 cells.
TFAM has been claimed to be required for maintenance of
normal levels of mtDNA and coordinating the assembly of
multiple DNA molecules into nucleoid-like structures [35,59–61].
The relative TFAM mRNA expression was 3- and 4-fold of
controls for p53+/2 and p532/2 (p=0.05 vs. controls), respectively,
proportional to the p53 gene dosage (Figure S5C). These results
suggested that p53 (directly or indirectly) affected TFAM gene
expression reciprocally, and that this factor (and may be others;
[62]) may ultimately control the mtDNA copy number.
The transcript levels of SCO2 were 40% in p53+/2 and 50% in
p532/2 of wild-type cells. In agreement with these results, protein
levels of p21 and SCO2 were 63% (p,0.001; Figures S5A &
S5B) and 75% (p,0.05; Figures S5A & S5B) of p53+/+ in p53+/2
cells. CCO activity was 61% (p,0.01; Figure S5C) and 21%
(p,0.01; Figure S5C) of WT in p53+/2 and p532/2 cells, not
necessarily accompanied by lower protein expression of CCO
subunits (mtDNA-encoded subunits II and III; not shown).
Consistent with these results, fibroblasts from patients with
SCO2 mutations have decreased CCO activity not associated
necessarily with changes in the expression of CCO protein
subunits [63].
These results confirmed previous reports that the sole p53
haplo-insufficiency influences the levels of SCO2 and that of CCO
activity [44] but expanded them by including the observation that
Pten protein levels are also modulated by p53 (p53+/2 cells had
75% of WT; p,0.05; Figures S5A & S5B).
Of note, although the decreases in p53 observed in HET-CRE
cerebellum and HCT 116 p53+/2 were comparable (40 to 42%;
Table 3, Figure S3 and Figure S5), some of the outcomes in
HET-CRE cerebellum (namely, SCO2, CCO/CS and MnSOD)
were similar to those observed in p532/2, while others fell between
those of p532/2 and p53+/2 (CCO), suggesting synergism between
Pten and p53 (negative feedback loop).
Discussion
Considering that disturbances in energy metabolism underlie
some neurological conditions such as schizophrenia, affective
disorders, fragile X-associated tremor and ataxia syndrome
(FXTAS) and autism [32,64–66], we tested if Pten haplo-
insufficiency in neural tissues resulted in the occurrence of aberrant
social and repetitive behavior and/or mitochondrial dysfunction,
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and evaluated the mechanism for such dysfunction. To this end, we
developed a Pten haplo-insufficient model, similar to the one
described by Parada’s group [14], but based on a two-step breeding
process (to reduce the genetic variability between littermates in the
second-generation mice). This approach allowed us to generate a
mouse model more representative of the heterozygous germline
mutations reported in children with autism [9–11,19,67] while
minimizing the risk for cancer development. Our results were
indicative of a mechanism that entailed a sustained activation of
PI3K/Akt pathway, for which Pten is a negative modulator,
followed by a negative feedback loop between Pten and p53
resulting in a specific decrease in CCO activity, ensuing in energy
stress in cerebellum and hippocampus.
Symptomatic mice presented lower CCO activity in both
cerebellum and hippocampus, deficits that paralleled those in p21
and SCO2 protein expression. It is interesting to note the interplay
between Pten, p53 and CCO, given that p53 is the only
transcription factor that has been found to be directly linked to
CCO activity [44,68]. Lower SCO2 (a metallochaperone involved
in the synthesis of subunit II of CCO and CCO maturation [69])
resulted in impaired CCO activity, along with the occurrence of
behavioral abnormalities in 20–29 weeks old mice. It is of interest to
note that SCO2 deficiency and/or CCO activity defects have been
reported in a number of patients with learning disabilities as well as
autism [32,70–73] and that a number of mutated proteins in ASD
had been found associated with p53-signaling pathway [13].
Considering that mtDNA deletions were significant in Pten
haplo-insufficient mice (20 to 29 weeks old) and that p53 has been
implicated in the maintenance of mtDNA (this study and others
[35,58,62]), among other genes [62], it could be argued that clonal
expansion of mtDNA with deletions can accumulate over time and
outnumber wild-type mtDNA [74]. It has been suggested that the
replicative advantage of large-scale deletions is due to a faster
completion of replication of smaller mtDNA molecules [75,76].
Although we observed that mtDNA deletions accumulate in
hippocampus with age in HET and, at a 2-fold increase in HET-
CRE mice (Figure 4) suggesting a higher copy-error probability,
to evidence a biochemical defect on CCO activity, the level of a
mtDNA deletion needs to exceed a critical threshold level of 50%
to 60% [77–79], level only reached at 1 year of age in HET-CRE
and close 2 years of age in HET according to our simulation (see
limitations of simulation in Figure 4, legend). Thus, deletions
acquired in later adult life of HET do not seem to have sufficient
time to express a biochemical defect and/or to reach significant
levels by random genetic drift alone, whereas in HET-CRE, and if
our model were correct, mtDNA deletions might exacerbate the
CCO deficiency initiated earlier by the PTEN-p53-SCO2 axis.
Furthermore, it is interesting to note that multiple mtDNA
deletions have been reported in association with psychiatric and
behavioral disturbances with slow progressive course and adult
onset [80–82] and possibly in the observed delayed phenotype of
Huntington’s disease (Napoli et al., 2012, submitted manuscript).
Several lines of evidence connect Pten and p53 functionally
(reviewed in [37]), including Akt-mediated phosphorylation of
MDM2 allowing MDM2-mediated ubiquitination and degrada-
tion of p53 [83–85] (Figure 5). A feedback loop has also been
suggested by the potential of p53 to regulate Pten transcription
[43]. This loop would explain our results obtained with the HCT
116 model in which the sole p53 haplo-insufficiency results in
decreased Pten protein levels. Social deficits present in conditional
Pten null mice were ameliorated by treatment with rapamycin [15],
indicating the involvement of the mTOR (mammalian target of
rapamycin complex) pathway. The latter observations, together
with our findings, predict a role for an mTOR-mediated response
to the earlier energy stress resulting from MD.
Over-expression of Pten in embryonic fibroblasts of transgenic
mice showed increased mitochondrial biogenesis and OXPHOS
capacity via PGC1a pathway activation [18]. Conversely,
decreases in Pten would be expected to result in decreased
mitochondria biogenesis and lower MnSOD (PGC1a is a positive
regulator of MnSOD transcription [86]). However, our model of
Pten haplo-insufficiency seem to point to the activation of a
mechanism that does not necessarily involve PGC1a, i.e., tissue-
specific regulation of Pten and p53 resulting in lower mitochon-
drial OXPHOS without significant changes in mitochondrial mass
(as judged by CS activity) and increased levels of MnSOD. This
apparent discrepancy can be bridged considering the differences in
biological models (generalized overexpression of Pten in utero vs.
specific knock-down of Pten in cerebellum and hippocampus at
postnatal stages).
Pten haplo-insufficient mice aged 20–29 weeks showed abnormal
social and repetitive behavior with some features similar to those
present in ASD, i.e., limited preference for social novelty, failure to
habituate to a familiar stimulus, social avoidance behavior and
repetitive or stereotyped behavior. Of note, atypical social
interactions are observed in many psychiatric disorders besides
Figure 4. mtDNA deletions in HET-CRE and HET hippocampus
accumulate with age. Accumulation of mtDNA with deletions
(average of deletions at the segments encoded for CYTB, COX3 and
ND4) with age per single hippocampal cell from HET (white circles) and
HET-CRE (black circles). The mtDNA deletions (represented as the mean
6 SEM) values were fitted to a linear regression (equations shown in the
figure) and the goodness of the regression was expressed as r2. From
the slope of each equation, the copy-error probability was estimated by
using the following formulae Ndel = (NmtDNA*Pdel*t * ln 2)/t1/2, where
Ndel is the number of mtDNA with deletions, t is the age of mice in days
throughout their lifetime (estimated as 2 years), NmtDNA = 1,200 mtDNA
copy number/cell (experimentally determined in hippocampus by
evaluating the ratio of mitochondrial ND1 gene copy number to the
nuclear PK gene copy number), and a mtDNA half-life (t1/2) of 10 d
[121]. For HET mice, a low copy-error probability was obtained
(9.561026) associated with a low incidence of accumulation of
deletions with age, becoming more significant towards the end of
their life. Higher copy-error probabilities, as that calculated with HET-
CRE mice (1.961025) lead to a greater accumulation of mtDNA with
deletions throughout a simulated mouse life. A biochemical defect on
CCO activity is evidenced when the level of a mtDNA deletion exceeds a
critical threshold level of 50%–60% [77] (indicated with a dotted line).
doi:10.1371/journal.pone.0042504.g004
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autism, including depression and schizophrenia [87,88]. In this
regard, an argument could be made that Pten haplo-insufficient mice
would serve as a better model for schizophrenia than autism given
that (i) the atypical social behavior observed in this study was not
observed until post adolescence when an autistic-like phenotype
would require a model in which the behavioral and anatomical
changes are present before adolescence (autism requires a diagnosis
before 3 years of age [89,90]) and (ii) mitochondrial dysfunction is
present in individuals with schizophrenia [91]. However, (i)
schizophrenia is characterized by reduced brain size [92,93]
whereas a subset of individuals with autism presents macrocephaly
[9,94–96]; (ii) schizophrenia tends to be associated with reduced
function of genes involved in the up-regulation of the PI3K/Akt
pathway [97,98] whereas autism has been associated with loss of
function of genes acting as negative regulators of the PI3K/Akt/
mTOR pathway [14,99]; (iii) in this regard, de novo Pten mutation
had been found strongly associated with increased risk of developing
ASD not schizophrenia [100]; and (iv) the difference in the onset
and full penetrance of aberrant social behavior in our study vs. those
utilizing a nullmodel [14,101] (i.e., our study 8–13 and 20–29 weeks
vs. 6–8 and 8–12 weeks for null models [14,101], respectively) and
the phenotypic characteristics (Lhermite-Duclos disease, Cowden
syndrome, and ASD, seizures, death vs. aberrant social and
repetitive behavior) seem consistent with a Pten gene dose effect
(i.e., this study, Cre2/+; Pten+/LoxP were haploid for Flox-Pten as
compared to previous studies, in which Flox-Pten was homozygous)
more than a set of developmental processes that result in a post-
adolescence behavioral phenotype.
Finally, it is worth mentioning the role of oxidative stress in Pten
haplo-insufficient mice also observed in CCO-deficient cybrids
constructed with mtDNA from patients with sporadic AD [102].
In addition, increased oxidative/nitrative stress might arise from
increased production of NO by eNOS, activated by the Akt
pathway, which is normally negatively regulated by PTEN; SCO2
deficiency resulting in oxidative DNA damage [103,104]; and
loss/decrease in assembled CCO - as it has been observed with
mutations in SCO2 [105] - could also affect the activity of
Complex III, the major site for ROS production in mitochondria
considering that the respiratory chain can exist as a supercomplex
[106]. Although we have not observed changes in SCCR activity
in Pten haplo-insufficiency, this biochemical assay does not
evidence relatively small changes in Complex III activity [107],
which could be significant in terms of ROS production.
This study underlines the importance of MD as a contributor to
either the development of symptoms and/or severity of the
phenotype. The final response to energy stress could be dependent
on a combination of genetic (Pten, p53, other genes) and/or
environmental factors [108,109] increasing the predisposition to
abnormal neurodevelopment [110,111] and resulting in a
convergent phenotypic characterized by aberrant social and
repetitive behavior. Indeed, energy-requiring processes that rely
heavily on mitochondrial OXPHOS and are necessary for typical
neurodevelopment, such as neuronal migration in the amygdala-
hippocampal region, have been found deficient in individuals with
ASD [112]. Alternatively, symptoms attributed to autism as well as
a number of neurological disorders [113,114], may result from an
imbalance of excitatory and inhibitory neurotransmission pro-
duced by an abnormal GABA catabolism which is linked to
mitochondrial function (‘‘GABA shunt’’; [115]), possibly com-
pounded by accumulation of mtDNA deletions.
Materials and Methods
Loxed Pten and Cre-loxed Pten mice
Mice expressing the Cre transgene under the control of the
neuron-specific enolase (Eno) promoter and a mouse expressing a
conditional-ready (i.e., loxP-flanked) phosphatase and tensin
homolog (Pten) gene were purchased from Jackson laboratories
(Tg(EnoCre) mice and Pten mice; JAX Stock #5938 and 6440,
respectively). After interbreedings of the ensuing 2 generations, a
generation of mutant mice in which the Pten gene was deleted only
in neural tissues (e.g., central nervous system neurons; spinal
neurons) was obtained. The benefit of the two-step breeding was a
reduction of genetic variability between littermates in the second-
generation mice. In addition, genotyping was used to screen for
hemizygosity of Cre-recombinase transgene. All other details
regarding genotyping of mice and animal housing had been
included under Methods S1. Detailed information on the mice
age, number, gender and test performed for these studies are
reported in Table 1.
Figure 5. Interplay between Pten and p53 and energy stress response mechanism to mitochondrial dysfunction. Deficits in Pten can
increase p53 degradation via Akt-mediated phosphorylation of MDM2 or by a feedback loop. Decreased levels of p53 leads to decreased levels of its
downstream effectors (p21 and SCO2), subsequent CCO deficiency, leading to increased oxidative stress and energy deficits (this and other reports
[44]). This would elicit the energy stress-mediated mTOR activation with consequent brain hypertrophy as observed in our haplo-insufficient Pten
mice as well as in the null mice models. Accumulation of mtDNA deletions (see Figure 4) may also ensue in MD contributing to the pathogenesis.
doi:10.1371/journal.pone.0042504.g005
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Ethics Statement
All animal procedures were conducted in strict compliance with
the policies on animal welfare of the National Institutes of Health.
All experiments performed with animals followed the protocol
#16183 (expiration date Dec 2, 2012) approved by IACUC at the
University of California Davis.
Behavioral test procedures
Upon transfer of the mice from the Mouse Biology Program
(UC Davis), where they were bred, to the behavioral laboratory
facility (UC Davis), mice were first evaluated for general health
[30,116,117], including body weight, body length, eye, fur and
whiskers physical conditions. The animals were housed three to
four mice/cage. Mice from the two groups appeared in good
general health (checked by a third-party veterinary staff), without
any overt impairments, aberrant responses or unusual levels of
activity or fighting during the home cage observation periods.
Behavioral testing began 4–6 days after arrival into the animal
facility. Mice were characterized in assays for sociability and
preference for social novelty. Order of testing for the mice was: 1)
general health observations upon arrival of mice at the behavioral
laboratory facility; 2) social behavior test. Unless otherwise
indicated, testing was conducted under fluorescent laboratory
lighting. All mice appeared to be healthy at the conclusion of the
testing sequence. All details on the behavioral tests had been
included in the Methods S1.
Cell Culture conditions and treatment with Pten inhibitor
Conditionally immortalized striatal neuronal progenitor cell lines
(STHdhQ7/Q7), obtained from the Coriell Cell Repositories, were
used in this study [118]. Frozen vials of striatal cells were thawed at
33uC. Cells (46105) were plated in T75 flasks and grown at 33uC in
a humidified atmosphere containing 5% CO2 with 20 ml of
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% FBS (Hyclone #SH30071.03), 104 I.U./ml Penicillin and
104 mg/ml Streptomycin (Gibco), without G418. After 24 h, the
media was changed to growth media without G418. When 70%
confluent, cells were trypsinized with 3 ml 0.25% Trypsin-EDTA
for 5 minutes to dissociate attached cells to the flask and then grown
in media with 0.4 mg/ml G418 at 33uC for 2–3 days until 70–80%
confluent. For Pten inhibition, cells were grown for 24 hours and
then treated with either 3 nM SF1670 (Cellagen Technology, San
Diego, CA) [56] or vehicle (DMSO) for another 24 hours at 33uC.
At the end of the incubation, cells were washed with PBS, detached
by trypsinization and viability was determined as explained above.
Average cell viability was 95% regardless of the treatment
performed.
Human colorectal carcinoma cell lines (HCT 116; ATCC
#CCL-247) whose genotype was p53+/+, p53+/2, or p532/2 were
grown in McCoy’s 5A modified medium supplemented with 10%
fetal bovine serum [119]. The media were supplemented with
penicillin 10 U/ml and streptomycin 10 mg/ml. All cell lines were
maintained at 37uC under 5% CO2 atmosphere. Details on
quantitative PCR analysis of HCT 116 cells were given in
Methods S1.
Mitochondrial enzymatic and Complex activities
Mitochondria from each brain region was isolated by differen-
tial centrifugation and purified through Percoll gradient to obtain
non-synaptosomal mitochondria. ‘‘Non-synaptosomal mitochon-
dria’’ includes the mitochondrial fraction minimally contaminated
with synaptosomes, i.e., vesicles that arise from nerve terminals
during tissue processing which rapidly reseal capturing other non-
mitochondrial components [120]. Individual activities of each
Complex were tested after lysing the organelles in 20 mM Hepes,
pH 7.4 supplemented with proteolytic and phosphatase inhibitors
(Sigma, cat # P2714 and P8849). NADH-decylubiquinone
oxidoreductase (NQR), NADH-ferricyanide reductase (NFR),
Succinate cytochrome c reductase (SCCR), Cytochrome c oxidase
(CCO), ATPase, and citrate synthase activities were evaluated as
described before in detail [32].
Western blotting procedures and analysis
Samples were homogenized in RIPA buffer and the protein
concentration was evaluated using a BCA Protein assay kit
(Pierce). Proteins were denatured in SDS-PAGE sample buffer
(BioRad) plus 5% 2-mercaptoethanol at 100uC for 5 min. Proteins
were run on an SDS-PAGE, transferred to PVDF membranes,
and probed with mouse monoclonal antibodies reactive to actin
(Sigma), b-ATPase (DB Transduction Laboratories), Akt (Cell
Signaling), p-Akt (Ser 473, Cell Signaling), MnSOD (Millipore),
nitrotyrosine (Millipore), p21 (Santa Cruz), p53 (1C12, Cell
Signaling), Pten (Millipore), SCO2 (Proteintech Group), and
tubulin (Sigma). Secondary antibodies were all from Invitrogen.
Proteins were visualized either with chemiluminescent reagents
(ECL) on a Kodak 2000 MM Imager or with fluorescence on an
Odyssey imager (LI-COR). The densitometry values were
normalized to actin, tubulin or b-ATPase as a loading control.
Evaluation of mtDNA copy number per cell and mtDNA
deletions
Tissues from mice were harvested and total genomic DNA was
isolated by using the Puregene kit from Qiagen, following the
manufacturer’s instructions (See also Figure S1). For evaluation
of mtDNA copy number per cell, quantitative real-time PCR
(QPCR) with dual-labeled probes was performed. The targeted
genes were the single-copy nuclear PK and mitochondrial CYTB,
ND1, ND4 and COX3. All other details were included in
Methods S1.
Statistical Analyses
The experiments were run in duplicate or triplicates and
repeated three times in independent experiments unless noted
otherwise. Data were expressed as mean 6 SEM. The data were
evaluated by using the t-test (StatSimple v2.0.5; Nidus Technol-
ogies, Toronto, Canada). For all comparisons, significance was set
at p#0.05.
Supporting Information
Method S1 Detailed information on some of the meth-
ods utilized in this study.
(DOCX)
Figure S1 Genotyping of HET-CRE mice for wild-type
and truncated Pten. Genomic DNA from various tissues from
HET (Pten+/loxP) and HET-CRE mice (Cre+/2; Pten+/loxP) was
extracted as described in Materials and Methods. Cre-mediated
Pten deletion in HET-CRE mice.
(TIF)
Figure S2 Nitrated b-ATPase levels in 20–29 weeks old
mice cerebellum. Representative Western blots and densitom-
etry results of nitrated b-ATPase in 20–29 weeks old mice
cerebella. Nitrotyrosine levels were normalized by total b-ATPase.
(TIF)
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Figure S3 Pten, p53, p21 and SCO2 levels in 4–29 weeks
old mice cerebellum. A. Representative Western blots of Pten,
p53, p21, SCO2 and respective actin levels in 8–13 and 20–29
weeks old mice cerebella (20–30 mg protein per lane). B. Average
expression of p53, p21 and SCO2 in 4–6, 8–13 and 20–29 weeks
old mice cerebella. HET: white bars; HET-CRE: black bars.
Statistically significant p values (p,0.05) calculated using Student’s
t test are also shown.
(TIF)
Figure S4 Pten, p53, and downstream effectors levels in
4–29 weeks old mice hippocampus. A. Representative
Western blots of Pten, p53, p21 and SCO2 (and respective actin)
levels in 8–13 and 20–29 weeks old mice hippocampus. Twenty to
thirty mg of proteins were loaded per lane. B. Average expression
of p53, p21 and SCO2 in 4–6, 8–13 and 20–29 weeks old mice.
HET: white bars; HET-CRE: black bars. Statistically significant p
values (p,0.05) calculated using Student’s t test are also shown.
(TIF)
Figure S5 Protein expression of p53 downstream effec-
tors and CCO activity in p53 haplo-insufficient HCT 116
cells. Representative Western blots (A) and densitometry (B) of
p53, p21, SCO2, Pten, MnSOD and actin (loading control) in
controls and p53 haplo-insufficient HCT 116 cells. Thirty mg of
protein were loaded into each lane if a 4–15% gels. MnSOD
expression was normalized by the beta subunit of ATPase (b-
ATPase, mitochondrial loading control). Results are expressed as
units of densitometry (AUD) normalized by actin, and reported as
mean 6 SEM (% of controls) of at least two experiments in
quadruplicate. Significant with * p,0.05; **p,0.01; ***p,0.001
to p53+/+. MtDNA copy number, mtDNA deletions, CCO activity
and TFAM mRNA levels (C) in p53 haplo-insufficient HCT 116
cells (p53+/2 and p532/2) are also shown as percentage of controls
cells (p53+/+). Percentage of mtDNA deletions were calculated as
follows: 1002(1006mtDNA gene ratio p53+/2 : p53+/+) or
1002(1006mtDNA gene ratio p532/2 : p53+/+). CCO activity
is expressed as nmol/min/mg protein and reported normalized by
citrate synthase (CS) as % of controls. Results are mean 6 SEM.
Significant with *p,0.05; **p,0.01; ***p,0.001 to p53+/+.
(TIF)
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